Trevi Therapeutics, Inc.
TRVI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $38 |
| Gross Profit | $0 | $0 | $0 | -$38 |
| % Margin | – | – | – | – |
| R&D Expenses | $10,085 | $9,389 | $7,811 | $9,328 |
| G&A Expenses | $3,831 | $4,333 | $3,659 | $0 |
| SG&A Expenses | $3,831 | $4,333 | $3,659 | $2,877 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $13,916 | $13,722 | $11,470 | $12,205 |
| Operating Income | -$13,916 | -$13,722 | -$11,470 | -$12,243 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2,099 | $1,400 | $1,119 | $844 |
| Pre-Tax Income | -$11,817 | -$12,322 | -$10,351 | -$11,399 |
| Tax Expense | -$15 | -$21 | -$11 | $16 |
| Net Income | -$11,802 | -$12,301 | -$10,340 | -$11,415 |
| % Margin | – | – | – | – |
| EPS | -0.08 | -0.094 | -0.088 | -0.11 |
| % Growth | 15.3% | -7.4% | 20.1% | – |
| EPS Diluted | -0.08 | -0.094 | -0.088 | -0.11 |
| Weighted Avg Shares Out | 145,105 | 130,350 | 117,611 | 106,010 |
| Weighted Avg Shares Out Dil | 145,105 | 130,350 | 117,611 | 106,010 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,101 | $1,407 | $1,125 | $843 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $38 | $38 | $37 | $38 |
| EBITDA | -$11,779 | -$12,284 | -$10,314 | -$11,360 |
| % Margin | – | – | – | – |